{"title": "Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI)", "author": "Sociedad Ecuatoriana De Alergia; Asma E Inmunologia", "url": "https://www.facebook.com/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0JzHnikPVCgtpXeDmywPHchDytBZfAgDAEFZuTFJtCz9QquAUMTHiME54A2JqVQeQl", "hostname": "facebook.com", "description": "Si la cadena de fr\u00edo se rompe en cualquier momento durante el transporte o almacenamiento, debido a la exposici\u00f3n a temperaturas extremas, entonces la potencia de la vacuna corre el riesgo de...", "sitename": "Si la cadena de fr\u00edo se rompe en cualquier momento durante el transporte o almacenamiento, debido a la exposici\u00f3n a temperaturas extremas, entonces la potencia de la vacuna corre el riesgo de reducirse o incluso la vacuna se vuelve completamente ineficaz. La gran mayor\u00eda de las vacunas deben refrigerarse entre 2 y 8 \u00b0 C, con un promedio preferido de 5 \u00b0 C con fluctuaciones m\u00ednimas. Los refrigeradores de laboratorio especialmente dise\u00f1ados se utilizan generalmente para este prop\u00f3sito, que tiene una fluctuaci\u00f3n de temperatura comparativamente m\u00ednima entre d\u00edas y estaciones, no presenta temperaturas extremas en ninguna superficie interior y puede tener una pantalla de temperatura externa que registra autom\u00e1ticamente la temperatura interna en intervalos de tiempo particulares . Muchas vacunas vivas toleran la congelaci\u00f3n y, seg\u00fan las instrucciones espec\u00edficas del fabricante, se congelan entre -15 y -50\u2070C. Entre las vacunas que se administran com\u00fanmente, esto incluye solo la varicela (varicela), el herpes z\u00f3ster (culebrilla) y la viruela, y la mayor\u00eda de las dem\u00e1s en lugar de refrigerarse. La mayor\u00eda de las vacunas no replicativas: virus o bacterias inactivados, subunidades de prote\u00ednas purificadas, ant\u00edgenos de carbohidratos y ant\u00edgenos de prote\u00ednas de subunidades recombinantes, se administran junto con adyuvantes como las sales de aluminio. Las sales de aluminio se han utilizado en vacunas en todo el mundo durante casi un siglo, actuando para formar un enlace i\u00f3nico con el ant\u00edgeno de inter\u00e9s en la vacuna, mejorando enormemente la estabilidad y la potencia. En a\u00f1os m\u00e1s recientes, se ha encontrado un prop\u00f3sito adicional potencialmente extremadamente significativo en el uso de adyuvantes de sal de aluminio, ya que parecen ayudar a promover una respuesta inmune mejorada del hu\u00e9sped despu\u00e9s de la administraci\u00f3n junto con una vacuna. Las sales de aluminio act\u00faan sobre los monocitos, macr\u00f3fagos y granulocitos para inducir citocinas, generando un ambiente inmunoestimulador local. Tambi\u00e9n pueden inducir necrosis local de las c\u00e9lulas del estroma, provocando la liberaci\u00f3n de \u00e1cido \u00farico que luego activa los inflamasomas. En cualquier caso, las sales de aluminio son muy sensibles al da\u00f1o por congelaci\u00f3n, ya que los ciclos de congelaci\u00f3n-descongelaci\u00f3n provocan la agregaci\u00f3n y sedimentaci\u00f3n de las part\u00edculas coloidales. Las altas temperaturas casi no afectan la estructura del gel de aluminio. Para obtener m\u00e1s informaci\u00f3n sobre el almacenamiento de vacunas, haga clic aqu\u00ed. De hecho, el da\u00f1o por congelaci\u00f3n a menudo es mucho m\u00e1s impactante que el da\u00f1o relacionado con el calor para las vacunas, aunque la mayor\u00eda de los fabricantes recomiendan no dejarlas reposar a temperatura ambiente durante m\u00e1s de treinta minutos, excepto en algunos casos especiales. A temperaturas extremas que se acercan y superan los 45 \u00b0 C, las prote\u00ednas presentes en la vacuna se desnaturalizan con relativa rapidez y, finalmente, pierden por completo su potencia cuando la estructura del ant\u00edgeno ya no est\u00e1 presente. Kumar y col. (1982) encontraron que una vacuna contra el t\u00e9tanos pod\u00eda sobrevivir a temperaturas de 35 \u00b0 C durante varias semanas, mientras que a 45 \u00b0 C experimentaban una p\u00e9rdida de potencia del 5% por d\u00eda durante las dos primeras semanas de almacenamiento. Cuando se expuso a temperaturas de 60 \u00b0 C, la vacuna se volvi\u00f3 completamente ineficaz despu\u00e9s de tres a cinco horas. Por el contrario, cuando se almacena a -30\u2070C durante doce horas, una vacuna contra el t\u00e9tanos pierde alrededor del 30% de potencia. Las prote\u00ednas presentes en la vacuna pueden da\u00f1arse directamente mediante ciclos de congelaci\u00f3n-descongelaci\u00f3n mediante varios mecanismos. Durante la congelaci\u00f3n r\u00e1pida se forman peque\u00f1os cristales de hielo, que necesariamente presentan una superficie m\u00e1s grande para las prote\u00ednas y, por lo tanto, es m\u00e1s probable que entren en contacto, causando da\u00f1os y un desdoblamiento parcial. Los cristales de hielo m\u00e1s grandes causan da\u00f1os m\u00e1s dr\u00e1sticos, envolviendo las prote\u00ednas y potencialmente da\u00f1ando el recipiente de la vacuna. Al descongelar, el proceso de recristalizaci\u00f3n ejerce tensi\u00f3n y esfuerzo cortante sobre las prote\u00ednas. El almacenamiento de las vacunas a temperaturas frescas tambi\u00e9n disminuye la necesidad de otros conservantes y disminuye el riesgo de crecimiento bacteriano dentro de la vacuna. Varios otros productos qu\u00edmicos pueden estar presentes en una vacuna, como trazas de antibi\u00f3ticos del proceso de fabricaci\u00f3n, estabilizadores como el sorbitol y reguladores de la acidez como la histidina, todos los cuales, a su vez, pueden verse afectados por temperaturas... - Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI)", "date": "2023-09-18", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Mehr von Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI) auf Facebook anzeigen\nMehr von Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI) auf Facebook anzeigen\noder\n[Neues Konto erstellen](/reg/?privacy_mutation_token=eyJ0eXBlIjowLCJjcmVhdGlvbl90aW1lIjoxNjk1MzEzNTkzLCJjYWxsc2l0ZV9pZCI6NjQ4NzMxOTgyNDk1ODQyfQ%3D%3D&rs=1)\n\u00c4hnliche Seiten\nAktueller Beitrag der Seite\nRoflumilast cream is a next generation topical phosphodiesterase typ...e 4 (PDE4) inhibitor. PDE4 \u2013 an established target in dermatology \u2013 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators. Roflumilast cream is uniquely formulated as a non-greasy emollient cream that absorbs quickly and spreads easily. In addition, roflumilast cream does not include sensitizing excipients or irritants such as propylene glycol, polyethylene glycol, isopropyl alcohol, ethanol, or fragrances. Roflumilast cream 0.3% (ZORYVE\u00ae) is approved by the FDA for the topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. Roflumilast cream for AD was evaluated at lower doses: 0.15% for adults and children 6 years of age and older and is being evaluated at 0.05% for children aged 2 to 5 years. About ZORYVE\u00ae ZORYVE (roflumilast) cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. IMPORTANT SAFETY INFORMATION The use of ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). The most common adverse reactions (\u22651%) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%).\n[Mehr anzeigen](/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0f7raHUG2QLxtAjdnYB3YsFojY5ZktdiGkJLW8qwx6FoPYrZaVQa4kZhwanM2MxuQl)\nArcutis Biotherapeutics, Inc announced that the INTEGUMENT-PED phase... 3 trial of roflumilast cream .05% met primary and secondary endpoints for treatment of mild to moderate atopic dermatitis (AD) in children ages 2 to 5 years.1 In the parallel group, double-blind, vehicle-controlled trial, 25.4% of children treated with roflumilast cream .05% achieved Investigator Global Assessment (IGA) Success compared with 10.7% of children treated with vehicle (P < .0001) at week 4. The steroid-free topical cream is used once daily and formulated to deliver the drug without disrupting the skin barrier. INTEGUMENT-PED evaluated roflumilast cream in 652 children with a mean Body Surface Area (BSA) of 22% overall. Roflumilast cream also met all secondary endpoints, including 39.4% of children achieving 75% improvement in Eczema Area and Severity Index (EASI-75), and 35.3% of children treated with roflumilast cream reaching a 4-point reduction in Worst Itch Numeric Scale (WI-NRS) compared to 18% of children treated with vehicle at week 4. \u201cAtopic dermatitis is a chronic disease that is unstable in its course. EASI-75 has emerged as an important endpoint in clinical trials and reflects clinically meaningful responses in the real world. EASI incorporates body surface area, and higher body surface area involvement is an important consideration for the severity and impact of the disease for patients suffering from pediatric atopic dermatitis,\u201d said Jonathan Silverberg, MD, PhD, MPH, FAAD, professor, Director of Clinical Research, and Director of Patch Testing at George Washington University School of Medicine and Health Sciences in Washington, DC, in a press release. Incidence of adverse events (AEs) during the trial was low, with the most common AEs in the roflumilast cream treated arm (\u2265 2%) being upper respiratory tract infection, pyrexia, diarrhea, and vomiting. Of the children randomized to receive roflumilast cream, 93.8% completed the 4 weeks of the study, with few discontinuing due to AEs (1.1% in the roflumilast group vs 1.9% in the vehicle group). Arcutis Biotherapeutics recently announced submission of a supplemental New Drug Application to the US Food and Drug Administration for roflumilast cream .15% for treating mild to moderate AD in adults and children aged 6 years and older. Reference Arcutis announces positive results from INTEGUMENT-PED pivotal phase 3 trial of roflumilast cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5. News release. September 19, 2023. Accessed September 19, 2023.\n[https://www.globenewswire.com/\u2026/Arcutis\u2026](https://l.facebook.com/l.php?u=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2023%2F09%2F19%2F2745482%2F0%2Fen%2FArcutis-Announces-Positive-Results-from-INTEGUMENT-PED-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html&h=AT3gNX-PocAxWYP8lC2NH_-m-xEAk6tBAsCifICRf1ChJ-urn5QQqME1L25brenBXX2NyVIkCK-hCsSsAN70XfIY_2b8U1yGPN8KHd2cqLZSPRIZIyUU9TIna-NHvT_jmaR1mvNLcF5C_E72_LMPC2wewjiQv91V) [Mehr anzeigen](/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0PdbsHHvcipGXCYTGERTf7Yc9UkUX432XnZPwsahurm5o93s7PR1oGzvYRaQgMDoEl)\nChronic urticaria (CU) is a mast cell (MC)-dependent disease with li...mited therapeutic options. Current management strategies are directed at inhibiting IgE-mediated activation of MCs and antagonizing effects of released mediators. Due to the complexity and heterogeneity of CU and other MC diseases and mechanisms of MC activation\u2014including multiple activating receptors and ligands, diverse signaling pathways, and a menagerie of mediators\u2014strategies of MC depletion or MC silencing (i.e., inhibition of MC activation via binding of inhibitory receptors) have been developed to overcome limitations of singularly targeted agents. MC silencers, such as agonist monoclonal antibodies that engage inhibitory receptors (e.g., sialic acid-binding immunoglobulin-like lectin8 -[Siglec-8] [lirentelimab/AK002], Siglec-6 [AK006], and CD200R [LY3454738]), have reached preclinical and clinical stages of development. In this review, we (1) describe the role of MCs in the pathogenesis of CU, highlighting similarities with other MC diseases in disease mechanisms and response to treatment; (2) explore current therapeutic strategies, categorized by nonspecific immunosuppression, targeted inhibition of MC activation or mediators, and targeted modulation of MC activity; and (3) introduce the concept of MC silencing as an emerging strategy that could selectively block activation of MCs without eliciting or exacerbating on- or off-target, immunosuppressive adverse effects.", "language": null, "image": "https://external-fra5-2.xx.fbcdn.net/emg1/v/t13/8714028298288757249?url=https%3A%2F%2Fwww.news-medical.net%2Fimage.axd%3Fpicture%3D2020%252f11%252fshutterstock_315807707.jpg&fb_obo=1&utld=news-medical.net&stp=c0.5000x0.5000f_dst-emg0_p400x400_q75&ccb=13-1&oh=06_AbFvFdSAK1ZV2rJs76ggsQLMrMu7-s62qLdNETWyz3jQRw&oe=650E0AC5&_nc_sid=528b31", "pagetype": "socialmediaposting", "links": ["https://www.facebook.com/", "https://www.facebook.com/recover/initiate?lwv=110&ars=royal_blue_bar", "/r.php?locale=de_DE", "/login/?privacy_mutation_token=eyJ0eXBlIjowLCJjcmVhdGlvbl90aW1lIjoxNjk1MzEzNTkzLCJjYWxsc2l0ZV9pZCI6Mzc4Mzc1MTU5OTY2NjIxfQ%3D%3D&next=https%3A%2F%2Ffacebook.com%2FSociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai", "/reg/?privacy_mutation_token=eyJ0eXBlIjowLCJjcmVhdGlvbl90aW1lIjoxNjk1MzEzNTkzLCJjYWxsc2l0ZV9pZCI6Mzc4Mzc1MTU5OTY2NjIxfQ%3D%3D&rs=2", "https://www.facebook.com/recover/initiate?lwv=110&ars=royal_blue_bar", "/reg/?privacy_mutation_token=eyJ0eXBlIjowLCJjcmVhdGlvbl90aW1lIjoxNjk1MzEzNTkzLCJjYWxsc2l0ZV9pZCI6NjQ4NzMxOTgyNDk1ODQyfQ%3D%3D&rs=1", "#", "https://facebook.com/lasid.org?ref=py_c", "https://facebook.com/lasid.org?ref=py_c", "https://facebook.com/hablemos.de.educacion?ref=py_c", "https://facebook.com/hablemos.de.educacion?ref=py_c", "https://facebook.com/100057349123732?ref=py_c", "https://facebook.com/100057349123732?ref=py_c", "https://facebook.com/redcivitic?ref=py_c", "https://facebook.com/redcivitic?ref=py_c", "https://facebook.com/SEBECUADOR?ref=py_c", "https://facebook.com/SEBECUADOR?ref=py_c", "https://facebook.com/adrianriverafilmmaker?ref=py_c", "https://facebook.com/adrianriverafilmmaker?ref=py_c", "https://facebook.com/FundacionIbeArte.Cultura?ref=py_c", "https://facebook.com/FundacionIbeArte.Cultura?ref=py_c", "https://facebook.com/SociedadEcuatorianaDePediatria?ref=py_c", "https://facebook.com/SociedadEcuatorianaDePediatria?ref=py_c", "https://facebook.com/slaai?ref=py_c", "https://facebook.com/slaai?ref=py_c", "https://facebook.com/sciartlatam?ref=py_c", "https://facebook.com/sciartlatam?ref=py_c", "https://facebook.com/100069740421991?ref=py_c", "https://facebook.com/100069740421991?ref=py_c", "https://facebook.com/drpablotorres.alergologo?ref=py_c", "https://facebook.com/drpablotorres.alergologo?ref=py_c", "https://facebook.com/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai", "#", "https://facebook.com/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0f7raHUG2QLxtAjdnYB3YsFojY5ZktdiGkJLW8qwx6FoPYrZaVQa4kZhwanM2MxuQl", "#", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0f7raHUG2QLxtAjdnYB3YsFojY5ZktdiGkJLW8qwx6FoPYrZaVQa4kZhwanM2MxuQl", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0f7raHUG2QLxtAjdnYB3YsFojY5ZktdiGkJLW8qwx6FoPYrZaVQa4kZhwanM2MxuQl", "https://facebook.com/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai", "#", "https://facebook.com/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0PdbsHHvcipGXCYTGERTf7Yc9UkUX432XnZPwsahurm5o93s7PR1oGzvYRaQgMDoEl", "#", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0PdbsHHvcipGXCYTGERTf7Yc9UkUX432XnZPwsahurm5o93s7PR1oGzvYRaQgMDoEl", "https://l.facebook.com/l.php?u=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2023%2F09%2F19%2F2745482%2F0%2Fen%2FArcutis-Announces-Positive-Results-from-INTEGUMENT-PED-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html&h=AT3gNX-PocAxWYP8lC2NH_-m-xEAk6tBAsCifICRf1ChJ-urn5QQqME1L25brenBXX2NyVIkCK-hCsSsAN70XfIY_2b8U1yGPN8KHd2cqLZSPRIZIyUU9TIna-NHvT_jmaR1mvNLcF5C_E72_LMPC2wewjiQv91V", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0PdbsHHvcipGXCYTGERTf7Yc9UkUX432XnZPwsahurm5o93s7PR1oGzvYRaQgMDoEl", "https://facebook.com/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai", "#", "https://facebook.com/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0JhMxx6mKU75UwZEV5jptSXQoy4vQFjkTc8jykt1maTahNtyvUpV6epG7bdhwfUnVl", "#", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0JhMxx6mKU75UwZEV5jptSXQoy4vQFjkTc8jykt1maTahNtyvUpV6epG7bdhwfUnVl", "/SociedadEcuatorianaDeAlergiaasmaEInmunologiaseaai/posts/pfbid0JhMxx6mKU75UwZEV5jptSXQoy4vQFjkTc8jykt1maTahNtyvUpV6epG7bdhwfUnVl", "https://www.facebook.com/490570534304779/posts/4080213472007116/", "https://tr-tr.facebook.com/490570534304779/posts/4080213472007116/", "https://pl-pl.facebook.com/490570534304779/posts/4080213472007116/", "https://it-it.facebook.com/490570534304779/posts/4080213472007116/", "https://ro-ro.facebook.com/490570534304779/posts/4080213472007116/", "https://fr-fr.facebook.com/490570534304779/posts/4080213472007116/", "https://ru-ru.facebook.com/490570534304779/posts/4080213472007116/", "https://ar-ar.facebook.com/490570534304779/posts/4080213472007116/", "https://es-la.facebook.com/490570534304779/posts/4080213472007116/", "https://pt-br.facebook.com/490570534304779/posts/4080213472007116/", "#", "/reg/", "/login/", "https://messenger.com/", "/lite/", "https://www.facebook.com/watch/", "/places/", "/games/", "/marketplace/", "https://pay.facebook.com/", "https://www.meta.com/", "https://www.meta.com/quest/", "https://l.facebook.com/l.php?u=https%3A%2F%2Fwww.instagram.com%2F&h=AT2kxsSYFB4j75t4MN87jLTS5TqLDO3YNGc9CSGqFXzIF3uk7O_PMIo8dapjZYiOByn3vvFr4TfDoTCK6E6WLv9i7wqwNJTxZeo_hU3HH0GgIXUy1bqQjRFu0ruFETD7xDJeTZvYKsBON34_", "https://l.facebook.com/l.php?u=https%3A%2F%2Fwww.threads.net%2F&h=AT2RmcruwvzkurknnHmyNoptCiC4r4GZ0MxXO9ekPH0z7csSz7GohIIidVctiBrury_VmIC0rjaDNJLjOQuWEgu2-Nv6DOdVuTlLo5BodSD1oDCDz-QWrQMWD5tZqp-_rtnHiqwRI--XqbhN", "/fundraisers/", "/biz/directory/", "/votinginformationcenter/?entry_point=c2l0ZQ%3D%3D", "/privacy/policy/?entry_point=facebook_page_footer", "/privacy/center/?entry_point=facebook_page_footer", "/groups/discover/", "https://about.meta.com/", "/ad_campaign/landing.php?placement=pflo&campaign_id=402047449186&nav_source=unknown&extra_1=auto", "/pages/create/?ref_type=site_footer", "https://developers.facebook.com/?ref=pf", "/careers/?ref=pf", "/policies/cookies/", "https://www.facebook.com/help/568137493302217", "/legal/terms?ref=pf", "/legal/germany/", "/help/?ref=pf", "help/637205020878504", "/settings", "/allactivity?privacy_source=activity_log_top_menu"]}